Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05598853 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intrathecal Double Checkpoint Inhibition

Study acronym: IT-IO
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 2, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Apr 2025 to Dec 2025 Trial status: Recruiting to Active, Not Recruiting · Site details revised at 3 of 3 sitesv5 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
  2. Study sites revised (3)v4 See this version in full on ClinicalTrials.gov ↗
  3. Site details revised at 1 of 3 sitesv3
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 2022 to Nov 25, 2022 · Site details revised at 3 of 3 sitesv2 Show 2 more changesShow less
    • Start date changed from estimate of Nov 2022 to Nov 25, 2022
    • Site details revised at 3 of 3 sites
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of the present study is to determine the feasibility and to explore anti-tumor activity of intrathecal double immune checkpoint inhibition for patients with newly diagnosed leptomeningeal metastases from non-small cell lung cancer without driver mutation or melanoma.
Trial Details
NCT Number NCT05598853
Lead Sponsor University of Zurich
Conditions Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV, Melanoma Stage IV
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov